Top 10 Medical AI Stocks on Wall Street’s Radar

2. Schrödinger Inc. (NASDAQ:SDGR)

Number of Hedge Fund Holders: 17

Schrödinger Inc. (NASDAQ:SDGR) leverages quantum mechanics in medicine and material design to assist biopharma firms and government laboratories in their research efforts. The company’s drug discovery programs in a range of therapeutic areas help reduce risk in drug development by identifying high-value targets through clinical validation. The declining cost of computation, the company’s protein structure prediction tech, and AI integration with its physics-based platform are expanding its ability to accelerate physics simulations and develop new tech called machine-learned force fields to accurately predict molecular properties.

Schrödinger Inc. (NASDAQ:SDGR) shares surged to above $24 after Hunterbrook Media, the media arm of Hunterbrook Capital, said on January 22nd that the firm is long on the company and described the company as a “key AI winner.” The company has consistently increased its software revenues over the years, but its unique position as a part-biotech, part-software business has presented valuation challenges for investors. However, the report stated: “Now Schrödinger has cautiously embraced AI, announced a new round of deals with partners ranging from Novartis to Nvidia, and this year will report clinical data from its first three internal drugs.”